Immune Repertoire Sequencing Market Size & Outlook, 2026-2034

Immune Repertoire Sequencing Market Overview

The global immune repertoire sequencing market size is estimated at USD 362.96 million in 2025 and is projected to reach USD 872.66 million by 2034, growing at a CAGR of 10.28% during the forecast period. Remarkable growth of the market is propelled by the rising adoption of high-depth immune profiling in oncology, increasing integration of receptor sequencing in cell therapy development, expanding use of repertoire analysis in infectious disease and vaccine research, and growing reliance on bioinformatics-driven platforms for advanced T cell and B cell characterization across academic, clinical, and commercial research settings.

Key Market Trends & Insights

• North America held a dominant share of the global market, accounting for 45.13% share in 2025.
• The Asia Pacific region is growing at the fastest pace, with a CAGR of 12.28%.
• Based on Product Type, the reagents and kits segment dominated the market with a revenue share of 43.42% in 2025.
• Based on Application, the oncology and cancer immunotherapy segment dominated the market with 39.43% share in 2025.
• Based on End User, the academic and research institutes segment dominated the market with a 48.98% share in 2025.
• The U.S. dominates the global market, valued at USD 134.73 million in 2024 and reaching USD 148.00 million in 2025.

Graph: U.S. Market Revenue Forecast (2022 – 2034)

Source: Straits Research

Market Size & Forecast

• 2025 Market Size: USD 362.96 million
• 2034 Projected Market Size: USD 872.66 million
• CAGR (2025 to 2034): 10.28%
• Dominating Region: North America
• Fastest-Growing Region: Asia Pacific

The immune repertoire sequencing market encompasses a wide range of products, platforms, and analytical tools designed to decode the diversity of T cell and B cell receptors for research, clinical, and therapeutic applications. The market includes reagents and kits such as DNA extraction kits, RNA extraction kits, library preparation kits, target enrichment kits, PCR amplification kits, and related consumables that support sample preparation workflows. It also comprises sequencing platforms, including Illumina-based systems, Oxford Nanopore devices, PacBio systems, and other instruments used to generate high-resolution immune profiling data. In addition, the market integrates software and services such as data analysis software, bioinformatics services, cloud-based platforms, custom sequencing services, and other computational solutions that enable interpretation of complex immune datasets. Immune repertoire sequencing is widely applied across oncology and cancer immunotherapy, autoimmune and inflammatory disease studies, infectious disease and vaccine development research, transplantation and immune tolerance monitoring, and various other immunology-focused fields. The market serves pharmaceutical and biotechnology companies, academic and research institutes, hospitals and clinical laboratories, contract research organizations, government and regulatory bodies, and additional end users that rely on detailed immune profiling to advance diagnostics, therapy development, biomarker discovery, and population-level immune research.

Latest Market Trends

Expansion of Single-Cell Immune Reconstruction Approaches

Research groups are increasingly adopting single-cell immune reconstruction methods that allow direct mapping of paired T cell and B cell receptors from individual cells. This approach provides deeper insight into clonal origin and receptor pairing patterns, encouraging wider usage of high-resolution assays that support single-cell workflows. Growing interest in understanding immune cell trajectories in early-stage disease studies is further accelerating the transition toward single-cell repertoire reconstruction.

Rising Integration of Long Read Sequencing for Extended Clonotype Coverage

Long read sequencing platforms are gaining traction in immune repertoire analysis due to their ability to capture full-length receptor sequences without fragmentation. Research laboratories are applying long-read approaches to study rare immune clones and extended VDJ combinations across diverse populations. This trend is strengthening the adoption of long-read-based workflows for complex immunology research, where a complete receptor structure is essential for accurate interpretation.

To get more insights about this report Download Free Sample Report

Market Driver

Growing Use of Repertoire Profiling in Cell Therapy Characterization

Cell therapy developers are using immune repertoire sequencing to track T cell expansion patterns, evaluate receptor persistence, and assess clonal dynamics following infusion. Increasing adoption of engineered cell therapies across oncology and genetic disorders has raised the requirement for detailed receptor-level characterization, which has strengthened market growth as developers integrate repertoire sequencing into their preclinical and clinical evaluation processes.

Market Restraint

Limited Access to High Quality Reference Databases for Diverse Populations

The market faces constraints due to insufficient reference datasets that represent wide genetic and ethnic diversity. Current repositories contain gaps in receptor sequences from underrepresented groups, which restricts accurate comparison and interpretation of immune profiles across populations. This shortage reduces uniformity in research findings and creates challenges for laboratories attempting to validate immune signatures across broader cohorts.

Market Opportunity

Rising Establishment of Regional Immunology Data Networks

Several countries are establishing coordinated immunology data networks that support centralized storage and analysis of large-scale immune sequencing datasets. These programs create avenues for laboratories to collaborate on multi-institutional immune profiling projects and expand the usage of repertoire sequencing tools. The formation of national-level data hubs encourages wider adoption of standardized sequencing workflows and opens new opportunities for vendors supplying advanced immune repertoire platforms and analytics.

Regional Analysis

North America accounted for the largest share of 45.13% in the immune repertoire sequencing market in 2025 due to the strong presence of genomics-focused companies and advanced research institutions that drive high adoption of sequencing-based immune profiling. The region also benefits from broad usage of genomic tools in oncology, infectious disease studies, and immune monitoring programs across academic centers and biopharma laboratories.

Growth in the U.S. is supported by rising preference for precision medicine programs that depend on detailed analysis of T cell and B cell diversity for patient stratification. A recent expansion of personalized oncology trials at institutions such as MD Anderson Cancer Center increased the use of immune repertoire sequencing panels for monitoring therapy response and clonal evolution in cancer patients, resulting in rising utilization across clinical research settings.

Asia Pacific Market Insights

Asia Pacific is the fastest-growing region with a CAGR of 12.28% due to the rising adoption of sequencing technologies in research facilities, along with expanding genomics funding across public and private sectors. Countries across the region are increasingly prioritizing advanced molecular tools in immunology and vaccine development, which is creating steady demand for immune repertoire sequencing platforms.

The Chinese market is expanding due to strong growth in biomedical research clusters and rising international collaborations in immunology. The development of large-scale national cohorts focused on chronic disease and infectious disease surveillance has increased the usage of immune repertoire sequencing to study immune signatures across large populations, driving further interest from academic and commercial laboratories.

Pie Chart: Regional Market Share, 2025

Source: Straits Research

Europe Market Insights

Europe is witnessing steady growth driven by regulatory frameworks that emphasize transparency in clinical research data and structured evaluation of molecular assays. These regulations have encouraged research organizations to adopt standardized sequencing-based immune profiling tools for oncology, autoimmune disorders, and cell therapy studies. The environment has also encouraged larger companies with strong compliance systems to expand their sequencing portfolios.

The market in the UK is growing due to the rising integration of immune profiling in clinical trials and translational research programs. Hospitals and research institutions, such as those under the NHS, initiated expanded usage of TCR and BCR sequencing for evaluating patient response patterns in advanced biologic therapies and cell-based treatments. This shift increased the adoption of repertoire analysis tools across leading research hubs.

Middle East and Africa Market Insights

The Middle East and Africa market is expanding with rising investment in molecular research laboratories and genomic medicine centers. Countries such as the United Arab Emirates, Saudi Arabia, and South Africa are establishing new research clusters focused on immunology and infectious disease, increasing usage of sequencing-based immune analysis.

In South Africa, the market is growing due to the rising burden of chronic conditions and infectious diseases that require a deeper understanding of immune system changes across large patient groups. Research articles published in regional medical journals highlighted expanded immunology studies at universities in Johannesburg and Cape Town where immune repertoire sequencing was adopted for studying immune alterations in long-term disease, supporting higher usage across academic research.

Latin America Market Insights

Latin America is experiencing steady growth supported by the modernization of research infrastructure and rising investment in genomic sciences. Governments and private research organizations are strengthening molecular biology capabilities in national laboratories, which has increased interest in immune repertoire sequencing for cancer research, immunotherapy development, and pathogen surveillance.

The Brazilian market is expanding due to its growing role in global oncology and vaccine development trials. Research institutes in São Paulo and Rio de Janeiro expanded sequencing-based immune monitoring programs to study T cell and B cell responses in cancer patients enrolled in new biologic therapy trials. This trend boosted demand for immune repertoire panels among clinical research laboratories.

Product Type Insights

The reagents and kits segment dominated the market with a revenue share of 43.42% in 2025. Growth in this segment is driven by high usage of DNA extraction kits, RNA extraction kits, library preparation kits, target enrichment kits, PCR amplification kits, and other consumables across research and clinical studies. These products are widely utilized during sample preparation, which makes them central to workflows in immunology laboratories that require detailed profiling of diverse immune cell populations.

The software and services segment recorded the fastest growth with a CAGR linked to its 11.12%. Rising adoption of data analysis software, bioinformatics services, cloud-based platforms, and custom sequencing services has boosted this segment as laboratories are managing larger volumes of immune repertoire data. Growing interest in advanced computational tools for clonotype tracking and immune diversity assessment continues to expand the usage of software-driven solutions.

Application Insights

The oncology and cancer immunotherapy segment dominated the market with a 39.43% share in 2025. High utilization of immune repertoire sequencing in tumor immune profiling, immunotherapy response monitoring, and clonal expansion studies has increased attention toward this application area. Research facilities and biopharma companies rely on detailed T cell and B cell analysis to understand tumor-related immune changes, driving demand in this segment.

The infectious diseases and vaccine development segment emerged as the fastest growing with 11.45%, driven by rising adoption of repertoire analysis for pathogen exposure studies, antibody maturation tracking, and vaccine response evaluation. Research groups involved in virology and bacterial disease studies are increasingly using sequencing-based immune profiling to evaluate population-level immune patterns, which supports the rapid expansion of this segment.

End User Insights

The academic and research institutes segment dominated the market with a 48.98% share in 2025. This dominance is due to strong interest in immunology studies, growing funding for genomic research, and widespread adoption of sequencing tools in universities and public research centers. These institutes frequently utilize immune repertoire sequencing for projects related to oncology, infectious diseases, and autoimmune conditions.

The pharmaceutical and biotechnology companies segment represented the fastest growth with 11.78%, supported by the rising integration of immune repertoire sequencing in drug discovery programs, biologics development, and clinical trial analysis. Companies engaged in monoclonal antibody development, cell-based therapies, and targeted immunotherapies are increasingly using repertoire profiling to guide pipeline advancement and patient response studies.

Source: Straits Research

Competitive Landscape

The global immune repertoire sequencing market is moderately fragmented, characterized by the presence of several global sequencing technology providers, specialized immunogenomics companies, and emerging niche players offering advanced profiling platforms and analytics at competitive pricing.

Adaptive Biotechnologies: An emerging market player

Adaptive Biotechnologies is a pioneering immune-driven company that focuses on decoding the human immune system through its proprietary immunosequencing platform, enabling applications in diagnostics, drug discovery, and immune profiling.

• In March 2025, Adaptive Biotechnologies expanded its immunoSEQ portfolio with new high-resolution TCR and BCR sequencing assays tailored for translational research, strengthening its leadership in immune repertoire analysis.

List of key players in Immune Repertoire Sequencing Market

1. Illumina, Inc.
2. Thermo Fisher Scientific, Inc.
3. PacBio
4. QIAGEN
5. BGI
6. Oxford Nanopore Technologies plc.
7. Agilent Technologies, Inc.
8. Takara Bio, Inc.
9. 10x Genomics.
10. Adaptive Biotechnologies
11. Creative Biolabs, Inc.
12. CD Genomics
13. Personalis, Inc.
14. Azenta US Inc.
15. Nucleus Biotech, Inc.
16. Celemics, Inc.
17. com
18. Others

To get more findings about this report Download Market Share

Strategic Initiatives

• June 2025: QIAGEN in the Netherlands partnered with US-based Incyte to develop an NGS-based multimodal companion diagnostic panel for CALR mutant myeloproliferative neoplasms, which was validated on Illumina’s NextSeq 550Dx platform.
• April 2025: QIAGEN in the Netherlands launched new QIAseq panels, expanded sequencing partnerships, and introduced HSMD Research, strengthening its NGS capabilities and contributing to rising demand for advanced profiling solutions in the immune repertoire sequencing market.